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Background: The use of imatinib, an ABL tyrosine kinase inhibitor, has led to a dramatic change in the
management of BCR-ABL-positive leukemia patients. However, resistance to imatinib mediated by mutations in the
BCR-ABL domain has become a major problem in the treatment of these patients.
Methods: In the present study, we examined the activity of histone deacetylase (HDAC) inhibitors in combination
with an Aurora kinase inhibitor in BCR-ABL-expressing cells.
Results: We found the HDAC inhibitors vorinostat and/or pracinostat (SB939) induced apoptosis in BCR-
ABL-expressing cells. Additionally, HDAC inhibitors reduced levels of Aurora A and B protein. An Aurora kinase
inhibitor, tozasertib (VX-680), inhibited growth, promoted pro-apoptotic activity, reduced the phosphorylation of
BCR-ABL and Crk-L, and activated caspase-3 and poly (ADP-ribose) polymerase (PARP) in BCR-ABL-positive cells.
Moreover, after treatment with tozasertib, HDAC protein expression was decreased. Combination of vorinostat or
pracinostat with tozasertib had a synergistic inhibitory effect on the proliferation of T315I cells. Phosphorylation of
Crk-L decreased, and PARP activation increased after treatment with vorinostat or pracinostat and tozasertib.
Moreover, combination of vorinostat or pracinostat and tozasertib significantly increased the extent of apoptosis in
primary chronic myeloid leukemia cells.
Conclusions: This study demonstrated that combination of HDAC and Aurora inhibitors was highly effective
against BCR-ABL-expressing cells.
Keywords: HDAC inhibitor, Aurora kinase inhibitor, T315I mutationBackground
Chronic myeloid leukemia (CML) is a hematopoietic dis-
order characterized by unregulated proliferation of predom-
inantly myeloid cells in the bone marrow [1]. BCR-ABL
fusion proteins resulting from the chromosomal transloca-
tion t(9;22) (the Philadelphia chromosome: Ph) cause CML
[2]. BCR-ABL activity leads to uncontrolled cell prolifera-
tion, reduced apoptosis, and malignant expansion of
hematopoietic stem cell populations. The ABL tyrosine kin-
ase inhibitor (TKI) imatinib has dramatically improved the* Correspondence: okabe@tokyho-med.ac.jp
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reproduction in any medium, provided the ormanagement and prognosis of patients with CML [3].
However, some patients, particularly those with advanced-
phase CML, have developed resistance to imatinib [4].
More than 50 distinct point mutations in the kinase do-
main of BCR-ABL have been detected in patients with
imatinib-resistant CML; point mutations in this domain are
the most frequent cause of acquired imatinib resistance in
CML patients [5,6]. Second-generation TKIs, such as
dasatinib and nilotinib, have shown promising results in
imatinib-resistant CML patients, but dasatinib and nilotinib
are not effective against CML clones with T315I mutations
[7]. Recently, ponatinib (also known as AP24534) was iden-
tified as a potent oral tyrosine kinase inhibitor and was
shown to block native and mutated BCR-ABL. Ponatinib isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing those with BCR-ABL T315I mutations [8]. However,
alternative strategies against point mutations (i.e., T315I)
within the BCR-ABL kinase domain are still important to
improve the prognosis of CML patients.
Histone deacetylases (HDACs) and histone acetyl-
transferases (HATs) are enzymes that regulate chromatin
structure and function [9]. Modification of histones
(e.g., via histone acetylation and deacetylation) plays an
important role in the regulation of gene expression [10].
Increased expression of HDACs and disrupted activities of
HATs have been observed in several tumor types [11].
HDAC inhibitors are emerging as potent antitumor agents
that induce cell cycle arrest, differentiation, and apoptosis
in many tumor cells of different origins. HDAC inhibitors
represent a new and promising class of antitumor drugs
[12]. HDAC inhibitors influence gene expression by en-
hancing histone acetylation. Because HDAC inhibitors
regulate many signaling pathways, cotreatment of HDAC
inhibitors with molecular targeted drugs, such as Aurora
kinase inhibitors, is a promising strategy against many
types of tumors.
This study aimed to examine the activity of the HDAC
inhibitors vorinostat and pracinostat (SB939) in vitro,
both alone and in combination with an Aurora kinase
inhibitor. This study also explored the molecular mecha-
nisms underlying treatment-related cell growth inhib-
ition and apoptosis in BCR-ABL-expressing cell lines
with point mutations. We found that the combination of
HDAC and Aurora kinase inhibitors significantly
inhibited cell growth in BCR-ABL-expressing cells.
Results and discussion
Activity of HDAC inhibitors in BCR-ABL-positive cells
HDACs have been identified as novel targets for the treat-
ment of hematologic malignancies, including Ph-positive
leukemia. HDACs regulate gene transcription, producing
disparate effects on cell growth and survival. Vorinostat, an
HDAC inhibitor, was approved by the FDA as therapy for
cutaneous T-cell lymphomas. Pracinostat is an oral HDAC
inhibitor that is currently in phase II clinical trials [13]. We
also reported previously that another HDAC inhibitor,
depsipeptide, an acetylated intracellular protein, is effective
against BCR-ABL-positive blastic crisis cells [14]. Because
vorinostat and other HDAC inhibitors induce cell cycle ar-
rest and apoptosis in tumor cells [15], we investigated
whether vorinostat or pracinostat would inhibit growth in
BCR-ABL-expressing cells. K562 and Ba/F3 T315I cells
were treated with vorinostat or pracinostat, and cell prolif-
eration was investigated. Treatment with vorinostat or
pracinostat for 72 h strongly and significantly inhibited the
growth of K562 and Ba/F3 T315I cells in a dose-dependent
manner (Figure 1A). HDAC inhibitors have been reported
to induce the degradation of both Aurora A and B kinasesthrough a proteasome-mediated pathway [16]. Because ab-
errant expression and activity of Aurora kinases occur in a
wide range of human tumors [17], inhibition or depletion
of Aurora kinases may provide a promising method to
delay the growth of leukemia cells. In this study, we investi-
gated the effects of vorinostat and pracinostat on Aurora
kinase expression by using K562 cells. K562 cells were
treated with vorinostat or pracinostat at the indicated con-
centration for 48 h and analyzed by immunoblotting. The
expression of Aurora A and B was dose-dependently re-
duced after treatment with vorinostat or pracinostat
(Figure 1B).
Analysis of the effects of an Aurora kinase inhibitor on
intracellular signaling in K562 cells
Because HDAC proteins are aberrantly expressed in many
types of cancers and have nonredundant functions in con-
trolling the hallmark phenotypes of cancer cells [15], we ex-
amined HDAC expression after treatment with an Aurora
kinase inhibitor in K562 cell lines using DNA and antibody
microarray techniques. We found that the relative levels of
HDAC gene expression in K562 cell lines were decreased
after tozasertib treatment. In contrast, expression of
apoptosis-related genes, including Bim, was increased
(Figure 2A). We next examined results of the protein array
studies. In K562 cells, we found that HDAC protein levels
were decreased and apoptosis-related protein expression
was increased after 24 h treatment with 1 μM tozasertib
(Figure 2B). To confirm these findings, we performed im-
munoblotting analysis. Additionally, after tozasertib treat-
ment, the expression of HDAC1, -2, -5, and −7 proteins
was significantly reduced, while that of Bim was increased
(Figure 2C).
Activity of the Aurora kinase inhibitor in wild-type and
mutant BCR-ABL-expressing cells
We next investigated the activity of tozasertib against wild-
type (wt) and mutant BCR-ABL-expressing cells. For this
study, we also used Ba/F3 cells expressing wt-BCR-ABL
and BCR-ABL with kinase domain mutations found fre-
quently in patients, including T315I. Tozasertib treatment
inhibited cell growth in mutant BCR-ABL-expressing cells
in a dose-dependent manner “data not shown”. Next, we
used flow cytometry with annexin V to examine whether
tozasertib could induce apoptosis in BCR-ABL-expressing
cells. Tozasertib induced apoptosis in the BCR-ABL-ex-
pressing cell line K562 (Figure 3A). We also examined
intracellular signaling. The phosphorylation of Abl and
Crk-L was decreased after tozasertib treatment (Figure 3B).
Caspase-3 and PARP levels were significantly increased
(Figure 3B). Similarly, the phosphorylation of Abl and Crk-
L was decreased, while caspase-3 and PARP expression
levels were increased in BCR-ABL-expressing Ba/F3 cells
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Figure 1 Effects of HDAC inhibitors on BCR-ABL-expressing cells. (A) K562 and mutant Ba/F3 cells (T315I) were treated with vorinostat or
pracinostat for 72 h. The number of viable cells was calculated for each group. *P < 0.05, vorinostat or pracinostat treatment versus control in the
same cell line. (B) K562 cells were treated with vorinostat or pracinostat at the indicated concentrations for 48 h. Total extracts were analyzed by
immunoblotting with anti-Aurora A and B Abs. Actin was used as the loading control. Band intensities were quantified using ImageJ software.
Results in A and B are representative of at least 3 reproducible experiments.
Okabe et al. Cancer Cell International 2013, 13:32 Page 3 of 9
http://www.cancerci.com/content/13/1/32tozasertib was effective in cell expressing wt-BCR-ABL and
BCR-ABL mutants like T315I.
Efficacy of cotreatment with HDAC and Aurora kinase
inhibitors in BCR-ABL-expressing cells
Next, we examined the intracellular signaling of HDAC
and Aurora kinase inhibitors. The expression of Aurora
A and B was reduced after cotreatment with vorinostat or
pracinostat and tozasertib. Survivin expression was alsodecreased, while PARP was activated after cotreatment
with vorinostat or pracinostat and tozasertib (Figure 4A).
These results suggested that vorinostat or pracinostat
affected Aurora kinase expression, while treatment with
vorinostat or pracinostat and tozasertib regulated intracel-
lular signaling pathways in BCR-ABL-positive cells. An in-
creased frequency of BCR-ABL point mutations has been
found in advanced-phase and recurrent cancers [18,19].
T315I and P-loop mutations, such as G250E, Y253F, and
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Figure 2 Analysis of the effects of tozasertib on BCR-ABL-expressing cells. (A) K562 cells were exposed to 1 μM tozasertib or PBS (control)
for 16 h. Gene expression data were validated with the Human Genome U133A Genechip. The bar graph shows the expression of HDAC and
apoptosis related genes in K562 cells after tozasertib treatment versus control. * P < 0.05 for comparison to the actin expression. (B, C) An
antibody expression microarray was performed as described in the Materials and Methods section. Protein expression was calculated using MS
Excel. Prior to immunoblotting, K562 cells were treated with tozasertib for 24 h. Total extracts were analyzed using anti-HDAC1, -2, -5, -7, and -Bim
Abs. Actin was used as the loading control. Band intensities were quantified using ImageJ software. Results in A, B, and C are representative of 3
different experiments. * P < 0.05 for comparison to the actin expression.
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http://www.cancerci.com/content/13/1/32E255K, are highly resistant phenotypes. Next, we investi-
gated whether cotreatment with vorinostat or pracinostat
and tozasertib caused growth inhibition in Ba/F3 T315I
cells and wt-BCR-ABL-positive K562 cells. Ba/F3 T315I
and K562 cells were treated with vorinostat or pracinostat
and tozasertib, and cell proliferation was examined. We
found that cotreatment with vorinostat or pracinostat and
tozasertib significantly inhibited cell growth in both wt-
BCR-ABL-positive cells and T315I-positive cells (Figure 4B
and C). We also performed statistical analyses to deter-
mine the combination index (CI) for vorinostat or
pracinostat and tozasertib, which was calculated according
to the method of Chou and Talalay [20]. Combination of
vorinostat or pracinostat with tozasertib resulted CI valuesof 0.396 and 0.765. These results suggested that combin-
ation of vorinostat or pracinostat with tozasertib synergis-
tically enhanced the toxicities of these drugs in T315I
positive Ba/F3 cells. Thus, we demonstrated that
tozasertib combined with vorinostat or pracinostat could
potentially overcome imatinib-resistance in mutant BCR-
ABL-expressing cells. Although high concentrations of
compounds were used in these experiments, signifi-
cantly higher plasma concentrations of these com-
pounds have been reported in clinical trials [21-23].
Additionally, we found that low concentrations of
vorinostat or pracinostat and tozasertib were not effica-
cious in short-term viability assays. However, simultan-
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Figure 3 Effects of tozasertib on BCR-ABL-expressing cells. (A) The percentage of apoptotic cells was estimated by annexin V assay after
culturing for 48 h with tozasertib. Results from 3 independent experiments were averaged. Error bars represent standard deviations. *P < 0.05,
tozasertib treatment versus control in the same cell line. (B, C) K562 and Ba/F3 wt and T315I BCR-ABL cells were treated with tozasertib for 24 h.
Total extracts were analyzed by immunoblotting with phospho-specific anti-Abl, -Crk-L, -cleaved caspase 3, and -cleaved PARP Abs. Actin was
used as the loading control. Band intensities were quantified using ImageJ software. Data are representative of 3 separate experiments.
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death following treatment with low concentrations of
these compounds.
Efficacy of cotreatment with HDAC and Aurora kinase
inhibitors in BCR-ABL-positive primary CML cells
Because cotreatment with HDAC and Aurora kinase
inhibitors induces significant inhibition of growth in BCR-
ABL-expressing cell lines, we next investigated the effects
of these compounds in BCR-ABL-positive primary CML
samples and blastic phase samples. Indeed, treatment with
tozasertib and vorinostat or pracinostat inhibited cell
growth in BCR-ABL-positive CML samples and blastic
phase samples (Figure 5A). Although we did perform statis-
tical analyses of the data, the sample size was too small
to obtain meaningful statistics. Intracellular signaling
was also examined. Cotreatment with both tozasertib
and vorinostat or pracinostat decreased apparent Crk-Lphosphorylation, while apparent PARP and acetyl histone
H4 activity was increased (Figure 5B), again indicating the
potential efficacy of tozasertib and vorinostat or pracinostat
in BCR-ABL-positive primary cells.
Conclusion
In the current study, HDAC inhibitors induced apoptosis
in BCR-ABL-positive leukemia cells. In particular, pro-
found inhibition of cell growth and induction of apoptosis
were observed in response to HDAC inhibitors in BCR-
ABL-positive K562 and mouse pro-B Ba/F3 cells with
ectopic expression of wt and mutant T315I. This response
was amplified by cotreatment with an Aurora kinase
inhibitor. In this study, we also demonstrated that Aurora
kinase proteins were degraded by vorinostat or pracinostat
in a dose-dependent manner (Figure 1B). Although the
levels of Aurora family proteins were not directly reduced
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Figure 4 Effects of vorinostat or pracinostat in combination with tozasertib in BCR-ABL-positive cells. (A) K562 cells were treated with
vorinostat or pracinostat and/or tozasertib for 24 h. Total cell lysates were immunoblotted with anti-survivin, -Aurora A and B, and -cleaved PARP
Abs. Actin or tubulin was used as the loading control. Band intensities were quantified using ImageJ software. (B) K562 cells were treated with
HDAC inhibitors (vorinostat or pracinostat) and/or tozasertib for 72 h. The number of viable cells was calculated for each group. (C) Ba/F3 T315I
cells were treated with HDAC inhibitors (vorinostat or pracinostat) and/or tozasertib for 72 h. The number of viable cells was calculated for each
group. Results in A, B, and C are representative of at least 3 reproducible experiments.
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http://www.cancerci.com/content/13/1/32of HDAC proteins (Figure 2A). As such, our data indicated
that vorinostat or pracinostat and tozasertib affected the
activities of both Aurora kinase and HDAC, in turn in-
creasing antitumor activity in this system. Clinical trials
using tozasertib have been discontinued. However, other
pan-Aurora/BCR-ABL dual inhibitors may exhibit a similar
{profile, and these continue to be studied clinically. Our
findings suggest that cotreatment with these compounds
and specific molecular-targeted drugs could benefit pa-
tients with leukemic BCR-ABL cells that are resistant to
more conventional treatments.Methods
Reagents and antibodies
The HDAC inhibitors vorinostat (SAHA, suberoylanilide
hydroxamic acid) and pracinostat (SB939) were provided
by Selleck Chemicals LLC (Houston, TX). Tozasertib
(VX-680, MK-0457) was kindly donated by Vertex Phar-
maceuticals Inc (Cambridge, MA). Stock solutions of
vorinostat, pracinostat, and tozasertib were dissolved in
dimethyl sulfoxide and subsequently diluted to the desired
concentration in growth medium. Anti-phospho-Abl,
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Figure 5 Effects of HDAC inhibitors and tozasertib on BCR-ABL-positive primary CML cells. (A) Primary CML cell samples and blastic phase
samples were cultured at a concentration of 4 × 105 cells/mL in the presence of HDAC inhibitors (vorinostat or pracinostat) and/or tozasertib for
72 h. The number of viable cells was calculated for each group. *P < 0.05, tozasertib treatment versus tozasertib with HDAC inhibitors in the same
line. (B) Primary cells were treated with HDAC inhibitors (vorinostat or pracinostat) and/or tozasertib for 24 h. Total extracts were analyzed by
immunoblotting with phospho-specific anti-Crk-L, -cleaved PARP, and -acetyl histone H4 Abs. Actin was used as the loading control. Band
intensities were quantified using ImageJ software. Results in A and B are representative of 3 different experiments.
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antibodies (Abs) were obtained from Cell Signaling Tech-
nology (Beverly, MA). Other reagents were obtained from
Sigma (St. Louis, MO).Cell culture
The human CML cell line K562 was obtained from
the American Type Culture Collection (ATCC, Ma-
nassas, VA). Ba/F3 wt-BCR-ABL cells and Ba/F3T315I cells were described previously [24]. These cells
were maintained in RPMI1640 medium supplemented
with 10% heat-inactivated fetal bovine serum with 1%
penicillin/streptomycin in a humidified incubator at
37°C.Cell proliferation assay
Cell proliferation analysis was performed as previously
described [25].
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Panorama Ab microarrays (Sigma) were analyzed according
to the manufacturer’s instructions. The arrays were scanned
using a GenePix Personal 4100A microarray scanner, and
normalization was carried out using the housekeeping pro-
tein included with the chip. The protein expression ratio
was calculated using MS Excel. Western blot analysis was
performed as previously described [26,27].
DNA microarray and microarray data analysis
DNA microarray analysis was performed as previously
described [28]. In brief, K562 cells were treated with
1 μM tozasertib for 16 h. Following incubation at 37°C,
the cells were washed twice with ice-cold phosphate-
buffered saline (PBS) and collected immediately for RNA
isolation. In this study, we used the Human Genome
U133A Genechip (Affymetrix Santa Clara, CA), which
contains more than 47,000 transcripts. Target prepar-
ation was carried out following the manufacturer’s ex-
pression analysis manual. All arrays were screened for
quality by standard methods, and the mean fluorescent
intensity for each probe set was determined.
Primary samples
This study was approved by the Institutional Review
Board of Tokyo Medical University, and informed con-
sent was provided by all patients in accordance with the
Declaration of Helsinki. Primary samples were obtained
from the peripheral blood of CML patients. Mono-
nuclear cells were isolated from blood samples and
separated by Lymphosepar (Immuno-Biological Labora-
tories Co., Gunma, Japan). The cells were cultured in
RPMI1640 medium containing 10% fetal calf serum and
analyzed as described.
Flow cytometory analysis
Cells were treated with the indicated concentrations of
tozasertib for 48 h. Annexin V/propidium iodide apop-
tosis assays were performed according to the manufac-
turer’s instructions (Beckman Coulter, Inc., Brea, CA).
The cells were gently mixed and immediately analyzed
by flow cytometry.
Statistical analysis
Differences between treatment groups, in terms of dose
response and apoptosis, were determined using Student’s t
test. P values of less than 0.05 were considered significant.
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